These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

919 related items for PubMed ID: 30661365

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. CGRP and Migraine: The Role of Blocking Calcitonin Gene-Related Peptide Ligand and Receptor in the Management of Migraine.
    Maasumi K, Michael RL, Rapoport AM.
    Drugs; 2018 Jun; 78(9):913-928. PubMed ID: 29869205
    [Abstract] [Full Text] [Related]

  • 5. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
    Chiang CC, Schwedt TJ.
    Prog Brain Res; 2020 Jun; 255():143-170. PubMed ID: 33008505
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class.
    Hargreaves R, Olesen J.
    Headache; 2019 Jun; 59(6):951-970. PubMed ID: 31020659
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The sense of stopping migraine prophylaxis.
    Al-Hassany L, Lyons HS, Boucherie DM, Farham F, Lange KS, Marschollek K, Onan D, Pensato U, Storch E, Torrente A, Waliszewska-Prosół M, Reuter U, European Headache Federation School of Advanced Studies (EHF-SAS).
    J Headache Pain; 2023 Feb 16; 24(1):9. PubMed ID: 36792981
    [Abstract] [Full Text] [Related]

  • 12. Calcitonin Gene-Related Peptide Antagonists for the Prevention of Migraine: Highlights From Pivotal Studies and the Clinical Relevance of This New Drug Class.
    Arca K, Reynolds J, Sands KA, Shiue HJ.
    Ann Pharmacother; 2020 Aug 16; 54(8):795-803. PubMed ID: 32019317
    [Abstract] [Full Text] [Related]

  • 13. Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine - a meta-analysis of randomized controlled trials.
    Xu D, Chen D, Zhu LN, Tan G, Wang HJ, Zhang Y, Liu L.
    Cephalalgia; 2019 Aug 16; 39(9):1164-1179. PubMed ID: 30789292
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Can calcitonin gene-related peptide monoclonal antibodies ameliorate writer's cramp and migraine?
    Suzuki K, Suzuki S, Fujita H, Sakuramoto H, Shioda M, Hirata K.
    Neuropsychopharmacol Rep; 2024 Jun 16; 44(2):482-484. PubMed ID: 38602109
    [Abstract] [Full Text] [Related]

  • 17. Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development.
    Bigal ME, Walter S, Rapoport AM.
    Headache; 2013 Sep 16; 53(8):1230-44. PubMed ID: 23848260
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis.
    Hou M, Xing H, Cai Y, Li B, Wang X, Li P, Hu X, Chen J.
    J Headache Pain; 2017 Dec 16; 18(1):42. PubMed ID: 28389966
    [Abstract] [Full Text] [Related]

  • 20. The CGRP Pathway in Migraine as a Viable Target for Therapies.
    Edvinsson L.
    Headache; 2018 May 16; 58 Suppl 1():33-47. PubMed ID: 29697153
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.